Close
  Indian J Med Microbiol
 

Figure 3: Patient number 1: 177Lutetium-prostate-specific membrane antigen scan 24 h after administration of the radiotracer (6.6 GBq). He is a 66-year-old man with multiple metastases in his lungs, bones, liver, and lymph nodes. His brain metastases had been treated by surgery and radiotherapy before radioligand therapy. He had also undergone treatment with docetaxel, cabazitaxel, abiraterone, and enzalutamide. Despite the diffuse metastases, the patient's baseline prostate-specific antigen dropped to 0.4 ng/ml, indicating a significant decline (−87.5%) after radioligand therapy

Figure 3: Patient number 1: <sup>177</sup>Lutetium-prostate-specific membrane antigen scan 24 h after administration of the radiotracer (6.6 GBq). He is a 66-year-old man with multiple metastases in his lungs, bones, liver, and lymph nodes. His brain metastases had been treated by surgery and radiotherapy before radioligand therapy. He had also undergone treatment with docetaxel, cabazitaxel, abiraterone, and enzalutamide. Despite the diffuse metastases, the patient's baseline prostate-specific antigen dropped to 0.4 ng/ml, indicating a significant decline (−87.5%) after radioligand therapy